[go: up one dir, main page]

CA3239040A1 - Analogues de mdma pour moduler l'activite de sert, de dat et/ou de net - Google Patents

Analogues de mdma pour moduler l'activite de sert, de dat et/ou de net Download PDF

Info

Publication number
CA3239040A1
CA3239040A1 CA3239040A CA3239040A CA3239040A1 CA 3239040 A1 CA3239040 A1 CA 3239040A1 CA 3239040 A CA3239040 A CA 3239040A CA 3239040 A CA3239040 A CA 3239040A CA 3239040 A1 CA3239040 A1 CA 3239040A1
Authority
CA
Canada
Prior art keywords
disorder
heteroaryl
aryl
personality
psychogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3239040A
Other languages
English (en)
Inventor
Glenn PULLELLA
Michael Gandy
Adrian Scaffidi
Jasmine KING
Matthew PIGGOTT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Western Australia
Original Assignee
University of Western Australia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021903836A external-priority patent/AU2021903836A0/en
Application filed by University of Western Australia filed Critical University of Western Australia
Publication of CA3239040A1 publication Critical patent/CA3239040A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'Invention concerne des analogues de 3,4-méthylènedioxyméthamphétamine (MDMA), des procédés pour leur préparation, des médicaments et des méthodes médicales de traitement comprenant lesdits analogues de MDMA, ainsi que des utilisations médicales desdits analogues de MDMA. Les analogues de MDMA sont capables de moduler l'activité de SERT, de DAT et/ou de NET.
CA3239040A 2021-11-26 2022-11-28 Analogues de mdma pour moduler l'activite de sert, de dat et/ou de net Pending CA3239040A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2021903836A AU2021903836A0 (en) 2021-11-26 Analogues
AU2021903836 2021-11-26
AU2022901261 2022-05-12
AU2022901261A AU2022901261A0 (en) 2022-05-12 Analogues
PCT/AU2022/051422 WO2023092195A1 (fr) 2021-11-26 2022-11-28 Analogues de mdma pour moduler l'activité de sert, de dat et/ou de net

Publications (1)

Publication Number Publication Date
CA3239040A1 true CA3239040A1 (fr) 2023-06-01

Family

ID=86538463

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3239040A Pending CA3239040A1 (fr) 2021-11-26 2022-11-28 Analogues de mdma pour moduler l'activite de sert, de dat et/ou de net

Country Status (5)

Country Link
EP (1) EP4436964A4 (fr)
JP (1) JP2024544586A (fr)
AU (1) AU2022399234A1 (fr)
CA (1) CA3239040A1 (fr)
WO (1) WO2023092195A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3519816A4 (fr) 2016-09-29 2020-05-06 The Regents of the University of California Composés pour l'augmentation de la plasticité neuronale
CN113784962B (zh) 2019-02-27 2025-04-25 加利福尼亚大学董事会 用于治疗脑部疾病的氮杂环庚三烯并-吲哚类和其他杂环
JP2025502615A (ja) 2021-12-15 2025-01-28 デリックス セラピューティクス，インク． フェノキシおよびベンジルオキシ置換サイコプラストゲンならびにその使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005154350A (ja) * 2003-11-26 2005-06-16 Japan Science & Technology Agency 不斉アリルアミンの合成方法
MXPA06006501A (es) * 2003-12-23 2006-08-23 Basf Ag Compuestos de 1-(azolin-2-il)amino-1,2-difeniletano para combatir insectos, aracnidos y nematodos.

Also Published As

Publication number Publication date
JP2024544586A (ja) 2024-12-03
EP4436964A4 (fr) 2025-10-08
WO2023092195A1 (fr) 2023-06-01
EP4436964A1 (fr) 2024-10-02
AU2022399234A1 (en) 2024-05-23

Similar Documents

Publication Publication Date Title
CA3239040A1 (fr) Analogues de mdma pour moduler l'activite de sert, de dat et/ou de net
CN109715613A (zh) 杂环化合物
AU2002237654B2 (en) Piperazine derivatives, their preparation and their use for treating central nervous system (CNS) disorders
JP2018534257A (ja) オキサスピロ誘導体、その製造方法、及び医薬におけるその適用
CN108137508B (zh) 5-ht2c受体激动剂和组合物及使用方法
HRP940890A2 (en) Novel(r)-5-carbamoyl-8-fluoro-3-n,n-disubstituted-amino-3,4-dihydro-2h-1-benozpyranes
CA3156060A1 (fr) Derives de 2-isoindol-1,3,4-oxadiazole utiles en tant qu'inhibiteurs de hdac6
EP3077390B1 (fr) Forme de sel cristalline de (s)-(2-(6-chloro-7-méthyl-1 h-benzo[d]imidazol- 2-yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone comme antagoniste des récepteurs à l'oréxine
JP6483105B2 (ja) ピペラジン誘導体および医薬としてのその使用
HK1225731B (en) Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
EA026500B1 (ru) Соединение 2-(пиридин-2-ил)-1,7-диазаспиро[4.4]нонан-6-он в качестве модулятора потенциал-зависимых натриевых каналов
JP6751161B2 (ja) フッ素含有トリアゾロピリジン系化合物、その製造方法、医薬組成物及び用途
IL291835A (en) Compositions that preferentially potentiate subtypes of gabaa receptors and methods of use thereof
AU2017201421B2 (en) Novel compounds
ITMI20120424A1 (it) Composti chimici
KR20090127313A (ko) 오렉신 길항제로서의 헤테로사이클
CA3157843A1 (fr) Modificateur de derive cyclique a quatre chainons, procede de preparation et application de celui-ci
Oberdorf et al. Thiophene bioisosteres of spirocyclic σ receptor ligands: Relationships between substitution pattern and σ receptor affinity
CN115108986A (zh) 阿朴菲衍生物及其制备方法和应用
JP6831376B2 (ja) トリアゾール誘導体
US12479838B2 (en) D3 receptor agonist compounds; methods of preparation; intermediates thereof; and methods of use thereof
JP2019509987A (ja) Ｅａａｔ３阻害剤としてのピラゾール−ピリジン誘導体
JP5642154B2 (ja) α７ｎＡＣｈＲのインドール誘導体モジュレータ
CN107735397A (zh) Gpr55受体活性选择性调节剂：苯并吡喃吡唑衍生物
JP2025538201A (ja) アリール基含有アミン系化合物、その製造方法及び使用